# Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

> **NCT00989196** · PHASE2 · COMPLETED · sponsor: **Octapharma** · enrollment: 22 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Human-cl rhFVIII
- **BIOLOGICAL:** Kogenate FS

## Key facts

- **NCT ID:** NCT00989196
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-10
- **Final completion:** 2012-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989196, "Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00989196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*